DXCM Operating cash flow
Operating cash flow at Dexcom rose to $1.4B in fiscal 2025, the highest in the 5 years reported, from $990M in 2024.
Net cash provided by operating activities, as filed.
SOURCE: us-gaap:NetCashProvidedByUsedInOperatingActivities · EDGAR CompanyFacts · CIK 1093557 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$1.4B
FY2024 $990M
HIGH$1.4B FY2025
LOW$442M FY2021
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Operating cash flow | Change |
|---|---|---|
| FY2025 | $1.4B | +$451M |
| FY2024 | $990M | +$241M |
| FY2023 | $748M | +$79M |
| FY2022 | $670M | +$227M |
| FY2021 | $442M | — |
More SAME DATA, OTHER VIEWS
Operating cash flow across coverage → · DXCM company view →
Revenue · Net income · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.